<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792998</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-1701-102</org_study_id>
    <nct_id>NCT02792998</nct_id>
  </id_info>
  <brief_title>A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects</brief_title>
  <official_title>A 2-Stage Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Tablets in Healthy Subjects in a Double-blind, Placebo-controlled, Multiple-ascending-dose Stage and an Open-label, Single-dose, Crossover Food-effect Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The objectives of this study are:

      Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile and pharmacodynamic
      (PD) effects of a range of doses of IW-1701 tablets administered orally to healthy subjects
      over 7 days of repeated dosing

      Stage 2: To assess the safety, tolerability, PK profile and PD effects of IW-1701 tablets
      administered orally to healthy subjects, in fed and fasted states, in an open-label,
      single-dose, 2-period, 2-sequence crossover study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Event</measure>
    <time_frame>47 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration [Cmax]</measure>
    <time_frame>47 Days</time_frame>
    <description>Maximum observed Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve during a dosing interval [AUC]</measure>
    <time_frame>47 Days</time_frame>
    <description>Area under the plasma concentration time curve during a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration [Tmax]</measure>
    <time_frame>47 Days</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>47 Days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IW-1701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IW-1701 tablets administered orally in multiple ascending dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-1701</intervention_name>
    <description>IW-1701 Tablet</description>
    <arm_group_label>IW-1701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an ambulatory male or female between 18 and 55 years old at the screening
             visit

          -  Subject's body mass index score is &gt; 18.5 and &lt; 30.0 kg/m2 at the screening visit

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             check-in and must agree to use double-barrier contraception throughout the duration of
             the study

          -  Subject is in good health and has no clinically significant findings on a physical
             examination

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  History of any clinically significant medical conditions

          -  Other exclusion criteria per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ICON Early Phase Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

